Shots:

• The acquisition includes upfront- milestones- and other consideration payments. Abexxa will continue to operate in the Arlington
• The acquisition will allow Boehringer to access Abexxa’s expertise and capabilities in targeting cancer-specific proteins by using its technology to develop cancer immunotherapies and Abs for solid cancers
• The acquisition also bolsters Boehringer’s commitment to identifying the tumor-antigen & other ways for targeting intracellular antigens. Abexxa has developed TCR like Abs that can be used to disrupt the NKG2A: HLA-E immune checkpoint axis in oncology

Ref: Businesswire | Image: MDDI